Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.
Freidinger
R M
RM
Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Williams
P D
PD
Tung
R D
RD
Bock
M G
MG
Pettibone
D J
DJ
Clineschmidt
B V
BV
DiPardo
R M
RM
Erb
J M
JM
Garsky
V M
VM
Gould
N P
NP
D000595:Amino Acid Sequence; D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D005260:Female; D007202:Indicators and Reagents; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008969:Molecular Sequence Data; D015394:Molecular Structure; D010121:Oxytocin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010456:Peptides, Cyclic / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats; D011945:Receptors, Angiotensin / Q000187:drug effects* / Q000378:metabolism; D018045:Receptors, Oxytocin; D017483:Receptors, Vasopressin; D012995:Solubility; D013329:Structure-Activity Relationship; D014599:Uterus / Q000378:metabolism
D007202:Indicators and Reagents; D010456:Peptides, Cyclic; D011945:Receptors, Angiotensin; D018045:Receptors, Oxytocin; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin; D010121:Oxytocin